Yazar "Altuntaş, Fevzi" için Fakülteler listeleme
-
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience
Tekgündüz, Emre; Göker, Hakan; Kaynar, Leylagül; Sarı, İsmail; Pala, Çiğdem; Doğu, Mehmet Hilmi; Altuntaş, Fevzi; Turgut, Burhan (Cig Media Group, Lp, 2016)In this retrospective, multicenter study, we evaluated the real-life outcomes of adult Philadelphia-positive acute lymphoblastic leukemia patients. The best results in terms of survival are achieved in patients who were ... -
Convalescent plasma therapy in patients with COVID-19
Altuntaş, Fevzi; Ata, Naim; Yigenoğlu, Tuğçe Nur; Başcı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Çelik, Osman; Turgut, Burhan (Pergamon-Elsevier Science Ltd, 2021)Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ... -
Convalescent plasma therapy in patients with COVID-19
Yigenoğlu, Tuğçe Nur; Hacıbekiroğlu, Tuba; Berber, İlhami; Dal, Mehmet Sinan; Baştürk, Abdulkadir; Namdaroğlu, Sinem; Altuntaş, Fevzi; Turgut, Burhan (Wiley, 2020)There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ... -
Convalescent plasma therapy in patients with COVID-19 (Letter)
Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Bascl, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Turgut, Burhan; Erkurt, Mehmet Ali (Pergamon-Elsevier Science Ltd, 2021)[No Abstract Available] -
COVID-19 clinical course and blood groups: Turkish population-based study
Dal, Mehmet Sinan; Ata, Naim; Altuntaş, Fevzi; Başcı, Semih; Yigenoğlu, Tuğçe Nur; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Tubitak Scientific & Technical Research Council Turkey, 2021)Background/aim: SARS-CoV-2 enters the cell through the binding of the S glycoprotein on the surface of the virus to the angiotensin-converting enzyme 2 (ACE-2) in the host cells and also SARS-CoV S protein binding to ACE-2 ... -
COVID-19 in hematopoietic cell transplant recipients
Altuntaş, Fevzi; Ata, Naim; Yigenoğlu, Tuğçe Nur; Başcı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springernature, 2021)In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ... -
Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients
Yigenoğlu, Tuğçe Nur; Başçı, Semih; Şahin, Derya; Ulaş, Turgay; Dal, Mehmet Sinan; Korkmaz, Serdal; Altuntaş, Fevzi; Turgut, Burhan (Pergamon-Elsevier Science Ltd, 2021)SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and ... -
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Sage Publications Ltd, 2020)Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ... -
The outcome of COVID-19 in patients with hematological malignancy
Yigenoğlu, Tuğçe Nur; Ata, Naim; Altuntaş, Fevzi; Başçı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Wiley, 2021)In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 ... -
The outcome of COVID-19 in patients with hematological malignancy (Letter)
Yigenoğlu, Tuğçe Nur; Başçı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Turgut, Burhan; Altuntaş, Fevzi (Wiley, 2021)[No Abstract Available] -
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springer-Verlag Italia Srl, 2022)Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course ... -
Philadelphia-positive acute lymphoblastic leukemia in daily practice: A multicenter experience.
Göker, Hakan; Tekgündüz, Emre; Sarı, İsmail; Pala, Çiğdem; Dogu, Mehmet Hilmi; Öztürk, Erman; Altuntaş, Fevzi; Burhan, Turgut (Lippincott Williams & Wilkins, 2013)[No Abstract Available] -
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
Akpınar, Seval; Doğu, Mehmet Hilmi; Çelik, Serhat; Ekinci, Ömer; Yönal Hindilerden, İpek; Dal, Mehmet Sinan; Altuntaş, Fevzi; Turgut, Burhan (Elsevier Inc., 2022)Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib ... -
Tyrosine kinase inhibitors and COVID-19
Başçı, Semih; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Turgut, Burhan; Altuntaş, Fevzi (Sage Publications Ltd, 2020)[No Abstract Available]